Assessing Digital Breast Tomosynthesis Impact on Early Cancer Detection: Insights from Consecutive Screening

Annika Jögi1, Kristin Johnson1, Sofia Wittgren1

  • 1From the Department of Oncology and Radiotherapy, Skåne University Hospital, Klinikgatan 5, 222 42 Lund, Sweden (A.J.); Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Center at Medicon Village, Lund University, Lund, Sweden (A.J.); Radiology Diagnostics, Department of Translational Medicine and Department of Imaging and Physiology (K.J., V.S., H.T., J.O., I.A., S.Z., P.R.B.) and Department of Radiation Physics (P.R.B.), Lund University, Skåne University Hospital; and Department of Imaging and Physiology (K.J., V.S., J.O., I.A., S.Z.) and Department of Rheumatology Lund (S.W.), Lund University Skåne University Hospital, Malmö, Sweden; Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden (S.W.); and Clinical Studies Sweden-Forum South, Skåne University Hospital, Malmö, Sweden (A.Å.).

Radiology
|July 30, 2024
PubMed
Summary

Digital breast tomosynthesis (DBT) improves breast cancer screening by increasing cancer detection rates, particularly for invasive cancers. This technology aids in earlier detection, especially of luminal A-like cancers, enhancing screening performance over consecutive rounds.